Suppr超能文献

相似文献

2
PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
Front Immunol. 2024 Jun 11;15:1415834. doi: 10.3389/fimmu.2024.1415834. eCollection 2024.
4
A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. Epub 2019 Feb 8.
6
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003771.
8
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Cancer Immunol Res. 2015 Mar;3(3):266-77. doi: 10.1158/2326-6066.CIR-14-0230-T. Epub 2014 Dec 26.
9
Nanocell targeting using engineered bispecific antibodies.
MAbs. 2015;7(1):53-65. doi: 10.4161/19420862.2014.985952.
10
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Mol Cancer Ther. 2018 Oct;17(10):2164-2175. doi: 10.1158/1535-7163.MCT-18-0026. Epub 2018 Aug 6.

引用本文的文献

1
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.
Nat Commun. 2025 Jul 14;16(1):6369. doi: 10.1038/s41467-025-61567-7.
2
3
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.
Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2425781122. doi: 10.1073/pnas.2425781122. Epub 2025 May 30.
5
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease.
Blood Adv. 2025 Jan 14;9(1):116-126. doi: 10.1182/bloodadvances.2022009187.
9
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.
Acta Pharmacol Sin. 2024 Oct;45(10):2186-2198. doi: 10.1038/s41401-024-01316-6. Epub 2024 Jun 10.

本文引用的文献

1
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
MAbs. 2019 May/Jun;11(4):639-652. doi: 10.1080/19420862.2019.1574521. Epub 2019 Feb 20.
3
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.
Sci Transl Med. 2018 Oct 17;10(463). doi: 10.1126/scitranslmed.aat5775.
4
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Mol Cancer Ther. 2018 Oct;17(10):2164-2175. doi: 10.1158/1535-7163.MCT-18-0026. Epub 2018 Aug 6.
5
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
Blood Adv. 2018 Jun 12;2(11):1250-1258. doi: 10.1182/bloodadvances.2017014373.
6
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.
8
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Sci Transl Med. 2017 Oct 4;9(410). doi: 10.1126/scitranslmed.aal4291.
9
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Pharmacol Ther. 2018 Feb;182:161-175. doi: 10.1016/j.pharmthera.2017.08.005. Epub 2017 Aug 20.
10
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.
Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验